1. Evolving Paradigms in Recurrent/Metastatic SCCHN

3. Introduction

4. Program Overview

5. NCCN Recommendations for a MDT for Patients With SCCHN

6. Role of MDT in Optimal Patient Management

7. MDT Management of SCCHN: All Voices Heard

8. Case: Initial Presentation (January 2015)

9. Case: Imaging at Presentation (January 2015)

10. Case: Investigations (January 2015)

11. Case: Diagnosis and Initial Treatment

12. Case Continuation: November 2015

13. Imaging: November 2015

14. Treatment: November 2015

15. Imaging: April 2016

16. Head and Neck Cancer: Prognostic Factors

17. Metastatic SCCHN: Watch and Wait Approach

18. Metastatic/Recurrent SCCHN: Treatment Considerations

19. NCCN Guidelines: Very Advanced Head and Neck Cancer

20. Platinum-Based Chemotherapy Plus Cetuximab*: EXTREME Trial

21. TPEx as First-Line Tx in Recurrent/Metastatic SCCHN: A Phase 2 GORTEC Study

22. Case Continuation: Treatment (April 2016)

23. Imaging: Treatment Response (December 2016)

24. Case Continuation: Disease Progression (February 2017)

25. Imaging: February 2017

26. Metastatic/Recurrent SCCHN: Treatment Considerations (cont)

27. Common Disease Progression in Metastatic/Recurrent SCCHN

28. Role of Immunotherapy in Metastatic/Recurrent SCCHN

29. Nivolumab for Recurrent SCCHN*: CheckMate 141

30. Efficacy and Safety of Pembrolizumab in Recurrent/Metastatic SCCHN
Efficacy and Safety of Pembrolizumab in Recurrent/Metastatic SCCHN*: KEYNOTE-012, a Phase 1b Study

31. KEYNOTE-040: Pembrolizumab vs Standard Treatment in Recurrent/Metastatic SCCHN

32. Data Sets Supporting the Use of Immunotherapy in Patients With Recurrent/Metastatic SCCHN

33. Recurrent/Metastatic SCCHN: Use of Single-Agent Chemotherapy

34. Clinical Trial Enrollment in Recurrent/Metastatic SCCHN

35. First-Line Use of Anti-PD-1 Immunotherapy for SCCHN

36. Anti-PD-1 Immunotherapy: AE Profile

37. Platinum-Based Chemotherapy Plus Cetuximab: Managing AEs

38. Immune-Related AEs Induced by Anti-PD-1 Immunotherapy

39. Case Continuation: Second-Line Treatment

40. Combination Immune-Oncology Agents in SCCHN

41. Conclusions

42. Abbreviations